



Omnipod 5 SECURE-T2D Pivotal Trial

Pod shown without necessary adhesive

Objective¹:

- Evaluate changes in A1C and glycemic outcomes with Omnipod 5 in a diverse adult population with type 2 diabetes (T2D)

Methods¹:

- Single-arm prospective trial at 21 US clinical centers
- Study participants: 18-75 years old with T2D
- Stable insulin regimen for at least 3 months prior to enrollment
- Participants used Omnipod 5 for 13 weeks

**14-day
standard therapy**
(pre-study regimen)



**13-week
Omnipod 5 use**



Pod shown without
necessary adhesive

Key Results¹:

- Omnipod 5 **improved A1C and TIR** with **no increase in hypoglycemia** in participants with T2D across diverse backgrounds and baseline therapies
- Participants using Omnipod 5 saw **reduction in daily insulin use**, with **negligible weight gain**
- Patients reported **high levels of satisfaction** with Omnipod 5 and reported significantly **reduced diabetes-related distress**

Significance^{1,2}:

Effectiveness of Omnipod 5 use was seen in adults with T2D regardless of background, prior therapy, or GLP-1 RA/SGLT-2i use, and regardless of carb-counting ability. These findings helped contribute to the evidence supporting ADA Standards of Care which state AID as the preferred insulin delivery for T2D and support Omnipod 5 use across a broad adult population, including those not previously considered for diabetes technology.

Scan QR code for
full study



Key Takeaways:

Participants represent the general population with T2D (N=305):



Hispanic/Latino or Black



Baseline A1C ≥8%



Using GLP-1 RA




Did not carb count prior to study




Pump naïve prior to study


1. Reduction in A1C after using Omnipod 5 for 3 months



2. Significant improvement in TIR (20%), with minimal TBR



3. Significant insulin reduction and minimal weight gain



• Number of participants using ≥100 U/d of insulin reduced from **31% to 10%** at 13 weeks

High overall satisfaction with Omnipod 5

- Significant improvement in patient-reported diabetes distress^a
- High system satisfaction, with **90%** willing to recommend Omnipod 5 to friends and family

a. Mean T2-DDAS total intensity score: Standard Therapy = 2.5, 3-mo Omnipod 5 = 2.2, p<0.001. Mean Proportion with T2-DDAS ≥2.0: Standard Therapy = 66%; 3-mo Omnipod 5 = 55%, p<0.001.

A1D, automated insulin delivery; GLP-1 RA, GLP-1 receptor agonist; SGLT-2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; T2-DDAS, Type 2 Diabetes Distress Assessment System; TBR, time below range; TIR, time in range.

Reference: Pasquel FJ, Davis GM, Huffman DM, et al. *JAMA Netw Open*. 2025;8(2):e2459348. doi:10.1001/jamanetworkopen.2024.59348

Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. RX only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for Important Safety Information.

©2026 Insulet Corporation. Omnipod, the Omnipod 5 logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation. INS-OHS-12-2025-00195 V1.0.